DM Capital

Convo Advanced Manufacturing is a reliable platform for biomanufacturing technology. It works to develop an integrated global biomanufacturing technology, tools, goods, and services.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

Rege Nephro Co., Ltd., established in 2019 and based in Kyoto, Japan, is a biotech company focused on the research, development, production, and marketing of therapeutics for renal diseases. The company leverages induced pluripotent stem cell (iPSC) technology, sourced from the Center for iPS Cell Research and Application at Kyoto University, to create innovative treatments for kidney, liver, and pancreas conditions. Rege Nephro develops drugs that utilize core seeds technology, which includes pluripotent stem cells capable of producing erythropoietin (EPO) and specific nephron progenitor cell markers. This approach aims to minimize the reliance on dialysis among patients with renal failure by offering effective therapeutic alternatives. Additionally, the company produces kidney organoids designed for nephrotoxicity screening, facilitating drug discovery in applied research.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Shang Gong is a Beijing Based Healthcare Start Up.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

IVIVA Medical, Inc., established in 2013 and headquartered in Beverly, Massachusetts, specializes in developing bio-artificial platforms and systems to address end-stage renal disease (ESRD). The company aims to alleviate the demand for donor organs by creating autologous tissue constructs that combine advancements in tissue engineering, 3D additive manufacturing, and stem cell biology. These innovative therapies seek to provide alternative treatments for the over 500,000 ESRD patients in the United States, where transplants are often the only definitive solution but remain inaccessible to many.

uLab Systems Inc. specializes in developing innovative software technology for digital dental treatment planning aimed at orthodontists. Founded in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create tailored treatment plans based on individual patient needs. Its proprietary architecture and fully automated features enable chairside treatment planning, allowing orthodontists to generate aligner movement plans and fabricate custom aligners in under five minutes. This technology empowers orthodontists to streamline their workflows, reduce laboratory fees, and achieve faster delivery of dental appliances.

eBrace specializes in the development and manufacturing of advanced digital 3D printing technology tailored for the dental industry. The company focuses on producing bracketless invisible appliances, customized lingual invisible appliances, and dentures. Through its research and development efforts, eBrace aims to deliver precise and detailed dental products that enhance orthodontic treatments, offering innovative solutions to meet the needs of dental professionals and their patients.

Jiahong DentalLab specializes in manufacturing and distributing a wide range of dental products and services. Their offerings include both fixed and removable dentures, orthodontic products, and other dental equipment. Notably, they provide advanced solutions such as CNC-pure titanium brackets, implant suprabridges, and zirconia all-ceramic bridges, catering to both dental professionals and patients worldwide. Additionally, they offer dental restoration services, aiming to enhance dental and oral health for their clients.